Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Depreciation & Amortization (2016 - 2026)

Corvus Pharmaceuticals' Accumulated Depreciation & Amortization history spans 12 years, with the latest figure at $29000.0 for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 31.82% to $29000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29000.0 through Mar 2026, up 31.82% year-over-year, with the annual reading at $100000.0 for FY2025, 0.0% changed from the prior year.
  • Accumulated Depreciation & Amortization came in at $29000.0 for Q1 2026, down from $100000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.3 million in Q1 2022 to a low of $21000.0 in Q2 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $65000.0 (2024), against an average of $347117.6.
  • Year-over-year, Accumulated Depreciation & Amortization tumbled 98.69% in 2023 and then soared 116.67% in 2024.
  • Corvus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $400000.0 in 2022, then plummeted by 50.0% to $200000.0 in 2023, then plummeted by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then tumbled by 71.0% to $29000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Accumulated Depreciation & Amortization are $29000.0 (Q1 2026), $100000.0 (Q4 2025), and $28000.0 (Q3 2025).